Key result
Persistent neutralizing antibodies in multiple sclerosis patients treated with IFNbeta were associated with a shorter mean time between first and second relapse (13 vs 21 months; p=0.0064).
Why the study?
Do persistent neutralizing antibodies reduce the clinical efficacy of IFNbeta in patients with multiple sclerosis?
Population
78 patients with multiple sclerosis treated with IFNbeta
Comparison
Persistent neutralizing antibody positive status vs Neutralizing antibody negative (NAb-) status
Design
Cohort, open-label
Authors
Loading...
Supports hypothesis that neutralizing antibodies reduce IFNbeta efficacy in MS; should not yet change practice pending confirmatory trials.
Cohort (n=78)
Open-label
Do persistent neutralizing antibodies reduce the clinical efficacy of IFNbeta in patients with multiple sclerosis?
Absolute Event Rate: 13% vs 21%
p-value: p=0.0064
The development of persistent neutralizing antibodies significantly reduces the clinical efficacy of interferon beta therapy in patients with multiple sclerosis.
Malucchi et al. (2004) conducted a cohort in Multiple sclerosis (n=78). Persistent neutralizing antibodies (NAb+) vs. NAb negative (NAb-) was evaluated on Mean time between first and second relapse (months) (p=0.0064). Persistent neutralizing antibodies in multiple sclerosis patients treated with IFNbeta were associated with a shorter mean time between first and second relapse (13 vs 21 months; p=0.0064).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: